Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06557512 · ClinicalTrials.gov registry record · NA

Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma

A NA study of Meningioma and Recurrent Meningioma, sponsored by University of California, San Francisco.

Recruiting
Registry status
NA
Development phase
23
Enrollment target
1
Study location

NCT06557512: Recruiting NA study of Meningioma and Recurrent Meningioma, sponsored by University of California, San Francisco.

NCT06557512 is a NA study of Meningioma and Recurrent Meningioma that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 23 participants, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06557512, a NA study of Meningioma and Recurrent Meningioma, is actively recruiting participants, sponsored by University of California, San Francisco.

RECRUITING
Registry status
NA
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill tumor cells and shrink tumors. Stereotactic radiosurgery is a type of external radiation therapy that uses special equipment to position a patient and precisely deliver radiation to tumors in the body. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. Hypofractionated stereotactic radiosurgery may be safe, tolerable, and effective in treating patients with grade II or recurrent grade I meningiomas after surgical resection.

Primary Outcome

Adverse events will be classified and graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. The proportion of CTCAE grade 3-5 toxicity within 1 year of radiation will be estimated along with the exact 90% confidence interval.

Conditions Studied

Meningioma Recurrent Meningioma Meningioma, Malignant

Interventions

  • PROCEDURE Computed Tomography (CT)
  • PROCEDURE Magnetic Resonance Imaging (MRI)
  • RADIATION Hypofractionated Stereotactic Radiosurgery (SRS)

Study Locations (1)

California

  • University of California, San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2024-12-13
Est. Completion 2029-09-30
Phase NA
University of California, San Francisco

1,713 total trials

What NCT06557512 shows while recruiting

NCT06557512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 98-participant average among 21 other Meningioma trials with a reported enrollment target (77% lower).

The record links to 3 conditions, with Meningioma appearing as the primary indexed condition, and to 3 interventions - of which Computed Tomography (CT) is the first listed.

NCT06557512 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT06557512 about?

NCT06557512 is a clinical study titled "Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma". This clinical trial tests the safety and effectiveness of hypofractionated stereotactic radiosurgery for treating patients who have undergone surgical resection for grade II meningiomas or grade I meningiomas that have come back after a period of improvement (recurrent). Radiation therapy uses high ...

What is the current status of trial NCT06557512?

This trial is currently recruiting. It is a NA study. The enrollment target is 23 participants. The study started on 2024-12-13. Estimated completion is 2029-09-30.

What conditions does trial NCT06557512 study?

This clinical trial studies the following conditions: Meningioma, Recurrent Meningioma, Meningioma, Malignant.

What interventions are being tested in trial NCT06557512?

The interventions under investigation include: Computed Tomography (CT) (PROCEDURE), Magnetic Resonance Imaging (MRI) (PROCEDURE), Hypofractionated Stereotactic Radiosurgery (SRS) (RADIATION).

Who is sponsoring clinical trial NCT06557512?

This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06557512 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Meningioma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06557512's enrollment target sits among peer trials

23 17th of 21 higher than 5 of 21 other Meningioma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Meningioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT06557512

Source: ClinicalTrials.gov NCT06557512, the US trial registry maintained by the National Library of Medicine. NCT06557512 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.